San Diego, CA, United States of America

Anjuli Timmer

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 4.8

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Anjuli Timmer: Innovator in Monoclonal Binding Agents

Introduction

Anjuli Timmer is a prominent inventor based in San Diego, CA. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal binding agents. With a total of 2 patents to her name, her work is paving the way for advancements in medical treatments.

Latest Patents

Anjuli Timmer's latest patents include innovative compositions that have the potential to revolutionize therapeutic approaches. One of her notable patents is focused on CMET monoclonal binding agents, drug conjugates thereof, and their uses. This patent presents compositions that specifically bind to the extracellular domain of cMET, offering new avenues for targeted therapies. Another significant patent involves Syndecan-1 (CD138) binding agents and their uses, which also highlights compositions that specifically bind to syndecan-1, further expanding the possibilities in medical applications.

Career Highlights

Anjuli Timmer is currently associated with Mitsubishi Tanabe Pharma Corporation, where she continues to drive innovation in her field. Her expertise and dedication to research have positioned her as a key figure in the development of new therapeutic agents.

Collaborations

Anjuli collaborates with talented professionals in her field, including Julia Coronella and Roland A Newman. These partnerships enhance her research efforts and contribute to the success of her projects.

Conclusion

Anjuli Timmer's work in monoclonal binding agents exemplifies the impact of innovative research in biotechnology. Her patents and collaborations reflect her commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…